WO1996011269B1 - Ligands tie-2, peocedes de production et utilisations de ces ligands - Google Patents
Ligands tie-2, peocedes de production et utilisations de ces ligandsInfo
- Publication number
- WO1996011269B1 WO1996011269B1 PCT/US1995/012935 US9512935W WO9611269B1 WO 1996011269 B1 WO1996011269 B1 WO 1996011269B1 US 9512935 W US9512935 W US 9512935W WO 9611269 B1 WO9611269 B1 WO 9611269B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ligand
- tie
- nucleic acid
- receptor
- human
- Prior art date
Links
- 239000003446 ligand Substances 0.000 title claims abstract 49
- 238000000034 method Methods 0.000 title claims abstract 28
- 101100481408 Danio rerio tie2 gene Proteins 0.000 title 1
- 101100481410 Mus musculus Tek gene Proteins 0.000 title 1
- 101000753291 Homo sapiens Angiopoietin-1 receptor Proteins 0.000 claims abstract 30
- 150000007523 nucleic acids Chemical class 0.000 claims abstract 29
- 108020004707 nucleic acids Proteins 0.000 claims abstract 17
- 102000039446 nucleic acids Human genes 0.000 claims abstract 17
- 108010090091 TIE-2 Receptor Proteins 0.000 claims abstract 15
- 102000012753 TIE-2 Receptor Human genes 0.000 claims abstract 15
- 239000005557 antagonist Substances 0.000 claims abstract 9
- 102000044214 human TEK Human genes 0.000 claims abstract 7
- 230000012010 growth Effects 0.000 claims abstract 4
- 239000000203 mixture Substances 0.000 claims abstract 4
- 230000000903 blocking effect Effects 0.000 claims abstract 3
- 230000001737 promoting effect Effects 0.000 claims abstract 3
- 102000005962 receptors Human genes 0.000 claims abstract 3
- 108020003175 receptors Proteins 0.000 claims abstract 3
- 206010029113 Neovascularisation Diseases 0.000 claims abstract 2
- 210000004204 blood vessel Anatomy 0.000 claims abstract 2
- 230000004614 tumor growth Effects 0.000 claims abstract 2
- 102100022014 Angiopoietin-1 receptor Human genes 0.000 claims 23
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 12
- 210000004027 cell Anatomy 0.000 claims 8
- 241000124008 Mammalia Species 0.000 claims 5
- 241001465754 Metazoa Species 0.000 claims 5
- 239000013612 plasmid Substances 0.000 claims 5
- 239000003937 drug carrier Substances 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 108091026890 Coding region Proteins 0.000 claims 2
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 claims 2
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 239000002254 cytotoxic agent Substances 0.000 claims 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims 2
- 238000003745 diagnosis Methods 0.000 claims 2
- 230000002068 genetic effect Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 101100454807 Caenorhabditis elegans lgg-1 gene Proteins 0.000 claims 1
- 241000238631 Hexapoda Species 0.000 claims 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 210000002889 endothelial cell Anatomy 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
- 230000004069 differentiation Effects 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Abstract
Cette invention se rapporte à une molécule d'acide nucléique isolée codant un ligand TIE-2 humain. Cette invention se rapporte en outre à un corps récepteur qui fixe spécifiquement un ligand TIE-2 humain, et à un anticorps qui fixe spécifiquement un ligand TIE-2 humain, ainsi qu'à un antagoniste de ligand TIE-2 humain. Cette invention se rapporte également à des compositions thérapeutiques et à un procédé pour bloquer la croissance des vaisseaux sanguins, à un procédé pour promouvoir la néovascularisation, à un procédé pour promouvoir la croissance ou la différenciation d'une cellule exprimant le récepteur de TIE-2, à un procédé pour bloquer la croissance ou la différenciation d'une cellule exprimant le récepteur de TIE-2, ainsi qu'à un procédé pour atténuer ou empêcher la croissance de tumeurs chez l'homme.
Priority Applications (27)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HK98105155.3A HK1005944B (en) | 1994-10-07 | 1995-10-06 | Tie-2 ligands, methods of making and uses thereof |
DE69520149T DE69520149T2 (de) | 1994-10-07 | 1995-10-06 | Tie-2 ligande, verfahren zu ihrer herstellung, und ihre anwendungen |
ES95939501T ES2154354T3 (es) | 1994-10-07 | 1995-10-06 | Ligandos tie-2, metodos para obtenerlos y sus usos. |
AU41295/96A AU711111B2 (en) | 1994-10-07 | 1995-10-06 | Tie-2 ligands, methods of making and uses thereof |
US08/817,318 US6433143B1 (en) | 1994-10-07 | 1995-10-06 | Tie-2 ligands |
NZ296638A NZ296638A (en) | 1994-10-07 | 1995-10-06 | Ligands which bind to tie-2 (tyrosine kinase with ig and egf homology domains) receptors |
EP95939501A EP0784683B1 (fr) | 1994-10-07 | 1995-10-06 | Ligands tie-2, procedes de production et utilisations de ces ligands |
AT95939501T ATE199259T1 (de) | 1994-10-07 | 1995-10-06 | Tie-2 ligande, verfahren zu ihrer herstellung, und ihre anwendungen |
DK95939501T DK0784683T3 (da) | 1994-10-07 | 1995-10-06 | TIE-2-ligander, fremgangsmåder til dannelse af disse og anvendelser deraf |
CZ19971025A CZ292453B6 (cs) | 1994-10-07 | 1995-10-06 | Izolovaná molekula nukleové kyseliny kódující TIE-2 ligand a její použití |
CA2202028A CA2202028C (fr) | 1994-10-07 | 1995-10-06 | Ligands tie-2, peocedes de production et utilisations de ces ligands |
MX9702530A MX9702530A (es) | 1994-10-07 | 1995-10-06 | Ligandos tie-2, metodos de preparacion y usos de los mismos. |
PL95319586A PL184642B1 (pl) | 1994-10-07 | 1995-10-06 | Izolowana czasteczka kwasu nukleinowego kodujaca ligand TIE-2, wektor zawierajacy izolowana czasteczke kwasu nukleinowego, izolowany i oczyszczony ligand TIE-2, uklad gospodarz-wektor, sposób wytwarzania izolowanego i oczyszczonego ligandu TIE-2, przeciwcialo, cialo ligandu, koniugat, kompozycja farmaceutyczna, zastosowanie przeciwciala, zastosowanie izolowanego i oczyszczonego ligandu, sposób in vitro podtrzymywania w hodowli ekspresji receptora TIE-2, sposób identyfikacji antagonisty receptora TIE-2, cialo receptora, izolowana czasteczka kwasu nukleinowego kodujaca cialo receptora, wektor zawierajacy izolowana czasteczke kwasu nukleinowego kodujaca cialo receptora, kompozycja farmaceutyczna zawierajaca cialo receptora PL |
HU9800160A HU221422B1 (en) | 1994-10-07 | 1995-10-06 | Tie-2 ligands, recombinant methods of making and uses thereof |
JP51267296A JP4054375B2 (ja) | 1994-10-07 | 1995-10-06 | Tie−2リガンド、その作製方法および使用方法 |
EP96910769A EP0821728B1 (fr) | 1995-04-06 | 1996-04-05 | Ligands tie-2, procedes d'obtention de ces ligands et leurs utilisations |
DE69633121T DE69633121T2 (de) | 1995-04-06 | 1996-04-05 | Tie-2 liganden, herstellungsverfahren und verwendung |
AU53871/96A AU715621B2 (en) | 1995-04-06 | 1996-04-05 | TIE-2 ligands, methods of making and uses thereof |
CA2216963A CA2216963C (fr) | 1995-04-06 | 1996-04-05 | Ligands tie-2, procedes d'obtention de ces ligands et leurs utilisations |
JP53053796A JP4122056B2 (ja) | 1995-04-06 | 1996-04-05 | Tie−2リガンド、その作製方法および使用方法 |
AT96910769T ATE273384T1 (de) | 1995-04-06 | 1996-04-05 | Tie-2 liganden, herstellungsverfahren und verwendung |
HK98109175.1A HK1008230B (en) | 1995-04-06 | 1996-04-05 | Tie-2 ligands, methods of making and uses thereof |
PCT/US1996/004806 WO1996031598A1 (fr) | 1995-04-06 | 1996-04-05 | Ligands tie-2, procedes d'obtention de ces ligands et leurs utilisations |
FI971406A FI120313B (fi) | 1994-10-07 | 1997-04-04 | TIE-2-ligandit, niiden valmistusmenetelmät ja käytöt |
NO19971557A NO322643B1 (no) | 1994-10-07 | 1997-04-04 | Isolert nukleinsyremolekyl som koder for TIE-2-ligand, TIE-2-ligand, fremgangsmate ved fremstilling og anvendelse derav, samt antistoff mot TIE-2-liganden. |
US09/442,717 US6627415B1 (en) | 1995-04-06 | 1999-11-18 | TIE-2 ligands, methods of making and uses thereof |
GR20010400568T GR3035717T3 (en) | 1994-10-07 | 2001-04-06 | Tie-2 ligands, methods of making and uses thereof |
Applications Claiming Priority (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/319,932 US5643755A (en) | 1994-10-07 | 1994-10-07 | Nucleic acid encoding tie-2 ligand |
US08/319,932 | 1994-10-07 | ||
US08/330,261 US5521073A (en) | 1994-10-07 | 1994-10-27 | TIE-2 ligand, and method of making |
US08/330,261 | 1994-10-27 | ||
US08/348,492 US5879672A (en) | 1994-10-07 | 1994-12-02 | Tie-2 ligand 1 |
US08/348,492 | 1994-12-02 | ||
US35350394A | 1994-12-09 | 1994-12-09 | |
US08/353,503 | 1994-12-09 | ||
US08/373,579 US5650490A (en) | 1994-10-07 | 1995-01-17 | Tie-2 ligand 2 |
US08/373,579 | 1995-01-17 | ||
US08/418,595 US5814464A (en) | 1994-10-07 | 1995-04-06 | Nucleic acids encoding TIE-2 ligand-2 |
US08/418,595 | 1995-04-06 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/418,595 Continuation US5814464A (en) | 1994-10-07 | 1995-04-06 | Nucleic acids encoding TIE-2 ligand-2 |
Related Child Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/817,318 A-371-Of-International US6433143B1 (en) | 1994-10-07 | 1995-10-06 | Tie-2 ligands |
PCT/US1996/004806 Continuation WO1996031598A1 (fr) | 1995-04-06 | 1996-04-05 | Ligands tie-2, procedes d'obtention de ces ligands et leurs utilisations |
US10/179,744 Division US20020173627A1 (en) | 1999-09-16 | 2002-06-24 | TIE-2 ligands, methods of making and uses thereof |
US10/179,615 Division US7063840B2 (en) | 1994-10-07 | 2002-06-24 | TIE-2 ligands, methods of making and uses thereof |
US10/179,820 Division US20030166858A1 (en) | 1999-09-16 | 2002-06-24 | TIE-2 ligands, methods of making and uses thereof |
Publications (3)
Publication Number | Publication Date |
---|---|
WO1996011269A2 WO1996011269A2 (fr) | 1996-04-18 |
WO1996011269A9 WO1996011269A9 (fr) | 1996-06-06 |
WO1996011269B1 true WO1996011269B1 (fr) | 1996-08-22 |
Family
ID=27559710
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1995/012935 WO1996011269A2 (fr) | 1994-10-07 | 1995-10-06 | Ligands tie-2, peocedes de production et utilisations de ces ligands |
Country Status (22)
Country | Link |
---|---|
US (4) | US5814464A (fr) |
EP (1) | EP0784683B1 (fr) |
JP (1) | JP4054375B2 (fr) |
CN (1) | CN1230536C (fr) |
AT (1) | ATE199259T1 (fr) |
AU (1) | AU711111B2 (fr) |
CA (1) | CA2202028C (fr) |
CZ (1) | CZ292453B6 (fr) |
DE (1) | DE69520149T2 (fr) |
DK (1) | DK0784683T3 (fr) |
ES (1) | ES2154354T3 (fr) |
FI (1) | FI120313B (fr) |
GR (1) | GR3035717T3 (fr) |
HU (1) | HU221422B1 (fr) |
IL (4) | IL115517A (fr) |
MX (1) | MX9702530A (fr) |
NO (1) | NO322643B1 (fr) |
NZ (1) | NZ296638A (fr) |
PL (1) | PL184642B1 (fr) |
PT (1) | PT784683E (fr) |
WO (1) | WO1996011269A2 (fr) |
ZA (1) | ZA958444B (fr) |
Families Citing this family (121)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5681714A (en) * | 1992-07-30 | 1997-10-28 | Mount Sinai Hospital Corporation | Nucleic acid encoding tek receptor tyrosine kinase |
US6221839B1 (en) | 1994-11-14 | 2001-04-24 | Helsinki University Licensing Ltd. Oy | FIt4 ligand and methods of use |
US6818220B1 (en) | 1994-11-14 | 2004-11-16 | Licentia Ltd. | Vascular endothelial growth factor C (VEGF-C) protein and gene mutants thereof, and uses thereof |
US6130071A (en) * | 1997-02-05 | 2000-10-10 | Helsinki University Licensing, Ltd. | Vascular endothelial growth factor C (VEGF-C) ΔCys156 protein and gene, and uses thereof |
US6245530B1 (en) | 1995-08-01 | 2001-06-12 | Ludwig Institute For Cancer Research | Receptor ligand |
US6645933B1 (en) | 1995-08-01 | 2003-11-11 | Helsinki University Licensing Ltd. Oy | Receptor ligand VEGF-C |
US6403088B1 (en) | 1995-08-01 | 2002-06-11 | Helsinki University Licensing, Ltd. | Antibodies reactive with VEGF-C, a ligand for the Flt4 receptor tyrosine kinase (VEGFR-3) |
JP4122056B2 (ja) * | 1995-04-06 | 2008-07-23 | リジエネロン ファーマシューティカルズ,インコーポレイテッド | Tie−2リガンド、その作製方法および使用方法 |
AU755337B2 (en) * | 1995-04-06 | 2002-12-12 | Regeneron Pharmaceuticals, Inc. | New uses of tie-2 ligands |
US6361946B1 (en) | 1997-02-05 | 2002-03-26 | Licentia Ltd | Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof |
US7423125B2 (en) | 1995-08-01 | 2008-09-09 | Vegenics Limited | Antibodies to VEGF-C |
EP0853668B2 (fr) | 1995-09-29 | 2013-03-06 | Vegenics Pty Ltd | Genes regules et leurs utilisations |
US7063965B2 (en) * | 1996-04-05 | 2006-06-20 | Regeneron Pharmaceuticals, Inc. | Nucleic acid encoding TIE-2 ligand |
DE19623850A1 (de) * | 1996-06-14 | 1997-12-18 | Wacker Chemie Gmbh | Homogenisierung von Dispersionen |
US6846914B2 (en) | 1996-06-19 | 2005-01-25 | Regeneron Pharmaceuticals, Inc. | Tie-2 ligand-3 |
US5851797A (en) * | 1996-06-19 | 1998-12-22 | Regeneron Pharmaceuticals, Inc. | Tie ligand-3, methods of making and uses thereof |
ES2194203T3 (es) * | 1996-06-19 | 2003-11-16 | Regeneron Pharma | Ligando del receptor tie-2 (ligando-4 de tie) y su uso. |
US6265564B1 (en) * | 1996-08-02 | 2001-07-24 | Regeneron Pharmaceuticals, Inc. | Expressed ligand-vascular intercellular signalling molecule |
DE69734359T2 (de) | 1996-08-23 | 2006-07-06 | Ludwig Institute For Cancer Research | Rekombinanter vaskulärer endothelzellen wachstumsfaktor d (vegf-d) |
US7125714B2 (en) | 1997-02-05 | 2006-10-24 | Licentia Ltd. | Progenitor cell materials and methods |
US5972338A (en) * | 1997-09-19 | 1999-10-26 | Genentech, Inc. | Tie ligands homologues |
US6350450B1 (en) | 1997-09-19 | 2002-02-26 | Genentech, Inc. | TIE ligand homologue antibody |
US6057435A (en) * | 1997-09-19 | 2000-05-02 | Genentech, Inc. | Tie ligand homologues |
US6030831A (en) * | 1997-09-19 | 2000-02-29 | Genetech, Inc. | Tie ligand homologues |
US6348350B1 (en) | 1997-09-19 | 2002-02-19 | Genentech, Inc. | Ligand homologues |
AU1931599A (en) * | 1997-12-19 | 1999-07-12 | Zymogenetics Inc. | Angiopoietin homolog, dna encoding it, and method of making it |
AU2000399A (en) * | 1997-12-19 | 1999-07-12 | Regeneron Pharmaceuticals, Inc. | Receptor tyrosine kinase, ar-1, is a regulator of angiogenesis |
AU2493699A (en) * | 1998-02-04 | 1999-08-23 | Zymogenetics Inc. | Angiopoietin homolog zapo3, dna encoding it, and method of making it |
AU746454B2 (en) | 1998-03-02 | 2002-05-02 | Massachusetts Institute Of Technology | Poly zinc finger proteins with improved linkers |
CA2322425A1 (fr) * | 1998-03-02 | 1999-09-10 | Millennium Pharmaceuticals, Inc. | Nouvelles molecules fdrg de proteines et d'acide nucleique et utilisation desdites molecules |
US7488590B2 (en) * | 1998-10-23 | 2009-02-10 | Amgen Inc. | Modified peptides as therapeutic agents |
WO2000027879A1 (fr) | 1998-11-10 | 2000-05-18 | Ludwig Institute For Cancer Research | Facteur de croissance d d'origine plaquettaire, l'adn codant pour celui-ci, et ses utilisations |
EP1141294B1 (fr) | 1998-12-23 | 2005-03-02 | Regeneron Pharmaceuticals, Inc. | Technique permettant d'accroitre l'activite biologique de ligands |
CA2362547A1 (fr) * | 1999-03-02 | 2000-09-08 | Regeneron Pharmaceuticals, Inc. | Proteine associee a l'angiopoietine et acides nucleiques correspondants |
US6455035B1 (en) | 1999-03-26 | 2002-09-24 | Regeneron Pharmaceuticals, Inc. | Angiopoietins and methods of use thereof |
US6703020B1 (en) | 1999-04-28 | 2004-03-09 | Board Of Regents, The University Of Texas System | Antibody conjugate methods for selectively inhibiting VEGF |
US6342219B1 (en) | 1999-04-28 | 2002-01-29 | Board Of Regents, The University Of Texas System | Antibody compositions for selectively inhibiting VEGF |
US6521424B2 (en) | 1999-06-07 | 2003-02-18 | Immunex Corporation | Recombinant expression of Tek antagonists |
ATE324444T1 (de) * | 1999-06-07 | 2006-05-15 | Immunex Corp | Tek-antagonisten |
AU5152700A (en) | 1999-06-15 | 2001-01-02 | Genentech Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US6689035B1 (en) | 2000-04-11 | 2004-02-10 | Gerber Scientific Products, Inc. | Method and apparatus for designing and creating a package |
JP2004537260A (ja) | 2000-12-07 | 2004-12-16 | サンガモ バイオサイエンシーズ, インコーポレイテッド | ジンクフィンガータンパク質による血管新生の調節 |
US7067317B2 (en) | 2000-12-07 | 2006-06-27 | Sangamo Biosciences, Inc. | Regulation of angiogenesis with zinc finger proteins |
US7521053B2 (en) * | 2001-10-11 | 2009-04-21 | Amgen Inc. | Angiopoietin-2 specific binding agents |
US7205275B2 (en) * | 2001-10-11 | 2007-04-17 | Amgen Inc. | Methods of treatment using specific binding agents of human angiopoietin-2 |
US7658924B2 (en) * | 2001-10-11 | 2010-02-09 | Amgen Inc. | Angiopoietin-2 specific binding agents |
US7138370B2 (en) | 2001-10-11 | 2006-11-21 | Amgen Inc. | Specific binding agents of human angiopoietin-2 |
AU2006228095B2 (en) * | 2001-10-11 | 2010-11-04 | Amgen Inc. | Angiopoietin-2 specific binding agents |
US20050123925A1 (en) | 2002-11-15 | 2005-06-09 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
US7052695B2 (en) | 2001-10-25 | 2006-05-30 | Regeneron Pharmaceuticals, Inc. | Angiopoietins and methods of treating hypertension |
JP4242590B2 (ja) | 2002-01-11 | 2009-03-25 | 俊一 塩澤 | 慢性関節リウマチの疾患感受性遺伝子、及びその利用 |
US7427594B1 (en) * | 2002-02-26 | 2008-09-23 | The Trustees Of The University Of Pennsylvania | Methods and pharmaceuticals compositions for treating coronary artery disease, ischemia,and vascular disease using angiopoietins |
US7081443B2 (en) | 2002-05-21 | 2006-07-25 | Korea Advanced Institutes Of Science And Technology (Kaist) | Chimeric comp-ang1 molecule |
US20040115640A1 (en) * | 2002-12-11 | 2004-06-17 | Isis Pharmaceuticals Inc. | Modulation of angiopoietin-2 expression |
EP1545588A4 (fr) | 2002-07-23 | 2007-12-05 | Ludwig Inst Cancer Res | Procedes et compositions pour l'activation ou l'inhibition du facteur de croissance endothelial vasculaire d et du facteur de croissance endothelial vasculaire c |
WO2004045531A2 (fr) | 2002-11-14 | 2004-06-03 | Cornell Research Foundation, Inc. | Protection du myocarge cardiaque |
SI1648998T1 (sl) | 2003-07-18 | 2015-01-30 | Amgen Inc. | Specifiäťna vezavna sredstva na hepatocitni rastni faktor |
CN1323723C (zh) * | 2003-12-26 | 2007-07-04 | 上海新世界基因技术开发有限公司 | Tie2受体介导的靶向性肿瘤基因治疗的基因转移系统 |
US8298532B2 (en) * | 2004-01-16 | 2012-10-30 | Regeneron Pharmaceuticals, Inc. | Fusion polypeptides capable of activating receptors |
US20060024302A1 (en) | 2004-03-05 | 2006-02-02 | Ludwig Institute For Cancer Research | Chimeric anti-VEGF-D antibodies and humanized anti-VEGF-D antibodies and methods of using same |
ES2339789T3 (es) | 2004-07-20 | 2010-05-25 | Genentech, Inc. | Inhibidores de proteina 4 de tipo angiopoyetina, combinaciones y su utilizacion. |
US8604185B2 (en) | 2004-07-20 | 2013-12-10 | Genentech, Inc. | Inhibitors of angiopoietin-like 4 protein, combinations, and their use |
HRP20110859T1 (hr) * | 2004-12-21 | 2011-12-31 | Medimmune Limited | Protutijela usmjerena na angiopoietin-2 i njihova upotreba |
CA2593612A1 (fr) * | 2005-01-07 | 2006-07-13 | Emory University | Antagonistes de cxcr4 pour le traitement de l'infection due au vih |
JP4657757B2 (ja) * | 2005-02-23 | 2011-03-23 | 株式会社膠原病研究所 | 肺高血圧症発症関連遺伝子を用いた肺高血圧症の診断および治療 |
JP2006325528A (ja) * | 2005-05-27 | 2006-12-07 | Institute For Rheumatic Diseases Co Ltd | 糖尿病性網膜症の診断および予防 |
JP4657857B2 (ja) * | 2005-08-25 | 2011-03-23 | 株式会社膠原病研究所 | メタボリックシンドロームの診断および予防 |
JP5179373B2 (ja) * | 2005-12-15 | 2013-04-10 | アストラゼネカ アクチボラグ | 癌を治療するためのアンジオポエチン−2アンタゴニストとVEGF−A、KDR、及び/又はFlt1アンタゴニストの組合せ |
AR059066A1 (es) | 2006-01-27 | 2008-03-12 | Amgen Inc | Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf) |
RS20080525A (en) | 2006-05-09 | 2009-09-08 | Pfizer Products Inc., | Cycloalkylamino acid derivatives and pharmaceutical compositions thereof |
DK2188313T3 (en) | 2007-08-21 | 2017-12-11 | Amgen Inc | HUMAN C-FMS ANTI-BINDING PROTEINS |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
US8227577B2 (en) * | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
US8557243B2 (en) | 2008-01-03 | 2013-10-15 | The Scripps Research Institute | EFGR antibodies comprising modular recognition domains |
US8557242B2 (en) | 2008-01-03 | 2013-10-15 | The Scripps Research Institute | ERBB2 antibodies comprising modular recognition domains |
US8454960B2 (en) | 2008-01-03 | 2013-06-04 | The Scripps Research Institute | Multispecific antibody targeting and multivalency through modular recognition domains |
US8574577B2 (en) | 2008-01-03 | 2013-11-05 | The Scripps Research Institute | VEGF antibodies comprising modular recognition domains |
AU2008346734A1 (en) | 2008-01-03 | 2009-07-16 | The Scripps Research Institute | Antibody targeting through a modular recognition domain |
US8507656B2 (en) | 2008-01-28 | 2013-08-13 | Medimmune Limited | Stabilized angiopoietin-2 antibodies and uses thereof |
JO2913B1 (en) | 2008-02-20 | 2015-09-15 | امجين إنك, | Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses |
EP2307456B1 (fr) | 2008-06-27 | 2014-10-15 | Amgen Inc. | Inhibition de l ang-2 pour traiter la sclérose en plaques |
US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
US8133979B2 (en) | 2008-12-16 | 2012-03-13 | Hoffmann-La Roche Inc. | Antibodies against human angiopoietin 2 |
CN102369215B (zh) * | 2009-04-02 | 2015-01-21 | 罗切格利卡特公司 | 包含全长抗体和单链Fab片段的多特异性抗体 |
SI2417156T1 (sl) | 2009-04-07 | 2015-06-30 | Roche Glycart Ag | Trivalentna, bispecifiäśna protitelesa |
US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
US8980268B2 (en) | 2009-07-29 | 2015-03-17 | Regeneron Pharamceuticals, Inc. | Methods for treating cancer by administering an anti-Ang-2 antibody |
US20120189635A1 (en) | 2009-07-29 | 2012-07-26 | Regeneron Pharmaceuticals, Inc. | Methods for Treating or Preventing Malaria by Administering an Antibody that Specifically Binds Angiopoietin-2 (Ang-2) |
CA2781519A1 (fr) | 2009-09-16 | 2011-03-24 | Genentech, Inc. | Complexes proteiques contenant une super-helice et/ou une attache et leurs utilisations |
US20120183546A1 (en) | 2009-09-23 | 2012-07-19 | Amgen Inc. | Treatment of ovarian cancer using a specific binding agent of human angiopoietin-2 in combination with a taxane |
AR080794A1 (es) | 2010-03-26 | 2012-05-09 | Hoffmann La Roche | Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2 |
TW201138821A (en) | 2010-03-26 | 2011-11-16 | Roche Glycart Ag | Bispecific antibodies |
US20120100166A1 (en) | 2010-07-15 | 2012-04-26 | Zyngenia, Inc. | Ang-2 Binding Complexes and Uses Thereof |
KR101586128B1 (ko) | 2010-08-24 | 2016-01-15 | 에프. 호프만-라 로슈 아게 | 디술피드 안정화 ― Fv 단편을 포함하는 이중특이적 항체 |
SG191153A1 (en) | 2010-12-23 | 2013-07-31 | Hoffmann La Roche | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery |
WO2012116927A1 (fr) | 2011-02-28 | 2012-09-07 | F. Hoffmann-La Roche Ag | Protéines monovalentes de liaison à l'antigène |
WO2012116926A1 (fr) | 2011-02-28 | 2012-09-07 | F. Hoffmann-La Roche Ag | Protéines de liaison à un antigène |
CA2837169C (fr) | 2011-05-24 | 2021-11-09 | Zyngenia, Inc. | Complexes multispecifiques contenant un peptide de liaison de l'angiopoietin-2 et utilisations connexes |
AU2012275346B2 (en) | 2011-06-29 | 2016-03-17 | Amgen Inc. | Predictive biomarker of survival in the treatment of renal cell carcinoma |
MX357393B (es) | 2012-01-23 | 2018-07-06 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti - ang2. |
JP6486686B2 (ja) | 2012-02-10 | 2019-03-20 | ジェネンテック, インコーポレイテッド | 単鎖抗体及び他のヘテロ多量体 |
AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
AU2013230750B2 (en) | 2012-03-08 | 2018-02-01 | Medimmune, Llc | Methods of treatment with Angiopoietin-2 antibodies |
RS58732B1 (sr) | 2012-03-30 | 2019-06-28 | Boehringer Ingelheim Int | Ang2 vezujući molekuli |
WO2014001325A1 (fr) | 2012-06-27 | 2014-01-03 | F. Hoffmann-La Roche Ag | Méthode de fabrication de conjugués d'anticorps à région fc comprenant au moins une entité de liaison qui se lie spécifiquement à une cible et leurs utilisations |
CN104395339A (zh) | 2012-06-27 | 2015-03-04 | 弗·哈夫曼-拉罗切有限公司 | 用于选择并产生含有至少两种不同结合实体的定制高度选择性和多特异性靶向实体的方法及其用途 |
NZ702201A (en) | 2012-07-13 | 2018-01-26 | Roche Glycart Ag | Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases |
WO2014108854A1 (fr) | 2013-01-09 | 2014-07-17 | Fusimab Ltd. | Anticorps anti-hgf et anti-ang2 monospécifiques, et anticorps anti-hgf/anti-ang2 bispécifiques |
US10150800B2 (en) | 2013-03-15 | 2018-12-11 | Zyngenia, Inc. | EGFR-binding modular recognition domains |
RU2016115866A (ru) | 2013-10-11 | 2017-11-16 | Ф. Хоффманн-Ля Рош Аг | Мультиспецифические антитела с обменянными доменами и одинаковыми вариабельными доменами легкой цепи |
BR112017005730B1 (pt) | 2014-09-26 | 2023-12-12 | Somalogic Operating Co., Inc | Método para triagem de um indivíduo quanto ao risco de um evento cardiovascular ou para predizer a probabilidade que um indivíduo tenha tal evento |
WO2016061551A1 (fr) | 2014-10-17 | 2016-04-21 | Amgen Inc. | Anticorps dirigés contre l'angiopoïétine 1 et l'angiopoïétine 2 pour thérapies oculaires |
PL3227332T3 (pl) | 2014-12-03 | 2020-06-15 | F. Hoffmann-La Roche Ag | Wielospecyficzne przeciwciała |
US20180037867A1 (en) | 2015-03-04 | 2018-02-08 | Mesoblast International Sàrl | Cell culture method for mesenchymal stem cells |
US20190004048A1 (en) | 2015-06-26 | 2019-01-03 | Amgen Inc. | Biomarker of Survival in the Treatment of Renal Cell Carcinoma with a VEGFR Inhibitor and an Ang2 Inhibitor |
DK3389636T3 (da) | 2015-12-16 | 2022-09-19 | Regeneron Pharma | Sammensætninger og fremgangsmåder til fremstilling af proteinmikropartikler |
CN109863171B (zh) | 2016-08-23 | 2023-08-04 | 免疫医疗有限公司 | 抗vegf-a和抗ang2抗体及其用途 |
US10925986B2 (en) | 2017-01-30 | 2021-02-23 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for reducing bioburden in chromatography |
WO2019075270A1 (fr) | 2017-10-12 | 2019-04-18 | Amesino Llc | Protéine de fusion à chaîne légère d'anticorps vegfr |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5116964A (en) * | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
AU8143094A (en) * | 1993-11-12 | 1995-05-29 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | (tie-2), a novel receptor tyrosine kinase |
US5879672A (en) * | 1994-10-07 | 1999-03-09 | Regeneron Pharmaceuticals, Inc. | Tie-2 ligand 1 |
WO2000002587A1 (fr) * | 1998-07-13 | 2000-01-20 | Board Of Regents, The University Of Texas System | Procedes de traitement du cancer mettant en application des conjugues therapeutiques se fixant a des aminophospholipides |
-
1995
- 1995-04-06 US US08/418,595 patent/US5814464A/en not_active Expired - Lifetime
- 1995-10-05 IL IL11551795A patent/IL115517A/en not_active IP Right Cessation
- 1995-10-06 AT AT95939501T patent/ATE199259T1/de active
- 1995-10-06 AU AU41295/96A patent/AU711111B2/en not_active Expired
- 1995-10-06 HU HU9800160A patent/HU221422B1/hu unknown
- 1995-10-06 US US08/817,318 patent/US6433143B1/en not_active Expired - Lifetime
- 1995-10-06 PT PT95939501T patent/PT784683E/pt unknown
- 1995-10-06 JP JP51267296A patent/JP4054375B2/ja not_active Expired - Lifetime
- 1995-10-06 CZ CZ19971025A patent/CZ292453B6/cs not_active IP Right Cessation
- 1995-10-06 WO PCT/US1995/012935 patent/WO1996011269A2/fr active IP Right Grant
- 1995-10-06 PL PL95319586A patent/PL184642B1/pl unknown
- 1995-10-06 MX MX9702530A patent/MX9702530A/es active IP Right Grant
- 1995-10-06 NZ NZ296638A patent/NZ296638A/xx not_active IP Right Cessation
- 1995-10-06 ES ES95939501T patent/ES2154354T3/es not_active Expired - Lifetime
- 1995-10-06 CN CNB951964658A patent/CN1230536C/zh not_active Expired - Lifetime
- 1995-10-06 EP EP95939501A patent/EP0784683B1/fr not_active Expired - Lifetime
- 1995-10-06 CA CA2202028A patent/CA2202028C/fr not_active Expired - Lifetime
- 1995-10-06 DK DK95939501T patent/DK0784683T3/da active
- 1995-10-06 DE DE69520149T patent/DE69520149T2/de not_active Expired - Lifetime
- 1995-10-06 ZA ZA1995/08444A patent/ZA958444B/en unknown
-
1997
- 1997-04-04 NO NO19971557A patent/NO322643B1/no not_active IP Right Cessation
- 1997-04-04 FI FI971406A patent/FI120313B/fi not_active IP Right Cessation
-
1998
- 1998-09-28 US US09/162,437 patent/US6166185A/en not_active Expired - Lifetime
-
2000
- 2000-10-12 US US09/689,020 patent/US6645484B1/en not_active Expired - Lifetime
- 2000-12-06 IL IL14013800A patent/IL140138A/xx not_active IP Right Cessation
- 2000-12-06 IL IL14013700A patent/IL140137A/xx not_active IP Right Cessation
-
2001
- 2001-04-06 GR GR20010400568T patent/GR3035717T3/el unknown
-
2003
- 2003-01-23 IL IL15411303A patent/IL154113A0/xx unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1996011269B1 (fr) | Ligands tie-2, peocedes de production et utilisations de ces ligands | |
CA2202028A1 (fr) | Ligands tie-2, peocedes de production et utilisations de ces ligands | |
CA2216963A1 (fr) | Ligands tie-2, procedes d'obtention de ces ligands et leurs utilisations | |
RU97107471A (ru) | Tie-2 лиганды, способы их получения и применения | |
JP3600617B2 (ja) | ヒト上皮細胞成長因子レセプターに特異的なモノクローナル抗体及びそれを用いた治療剤 | |
US6399068B1 (en) | Method of treatment with a non-antigenic toxin-conjugate and fusion protein of internalizing receptor system | |
JP3589459B2 (ja) | 生物応答調節物質の新規な抗体運送システム | |
AU618722B2 (en) | Recombinant pseudomanas exotoxin: construction of an active immunotoxin with low side effects | |
DE69129421T2 (de) | Interleukin 2 enthaltende rekombinante Immunkonjugate für die Therapie | |
AU631545B2 (en) | Il-2 receptor-specific chimeric antibodies | |
EP3444277A1 (fr) | Nanocorps anti-pd-l1, séquence de codage et utilisation associées | |
JP3541296B2 (ja) | 腫瘍血管内皮細胞に特異的に結合するモノクローナル抗体とその利用方法 | |
AU6084694A (en) | Methods of delivering agents to target cells | |
Ross et al. | Increased Toxicity of Diphtheria Toxin for Human Lymphoblastoid Cells following Covalent Linkage to Anti‐(human lymphocyte) Globulin or Its F (ab′) 2 Fragment | |
CA2097060A1 (fr) | Anticorps bifonctionnels et leur methode de preparation | |
WO1994009149A1 (fr) | Anticorps monoclonal | |
DE69934903T2 (de) | Mitogene regulatoren | |
JPH08501925A (ja) | 糖蛋白pに対するモノクローナル抗体 | |
WO1989010133A1 (fr) | Inhibiteurs de cellules a tiges | |
CN114685670B (zh) | Cldn18.2抗体及其应用 | |
AU2002354096B2 (en) | Cytotoxic protein and utilization thereof | |
JPH115749A (ja) | 癌治療医薬品組成物 | |
AU673858B2 (en) | Monoclonal antibody | |
CN113321730B (zh) | Cldn18.2抗体及其应用 | |
DE69925817T2 (de) | Rekombinante onconase und fusionsproteine davon |